# Harbinger Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/harbinger-health

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.harbinger-health.com/
- Total disclosed funding: $140M
- Latest round: Series B (Sep 28, 2023)
- Investors on record: 5

## About

Founded in 2018 and based in Massachusetts, US, Harbinger Health, Inc. operates as a biotechnology company that focuses on detecting early signs of cancer using artificial intelligence-based technology. In April 2026, Harbinger Health, Inc. raised USD 100 million in venture funding led by Flagship Pioneering.
The company is at the forefront of early cancer detection, revolutionizing cancer screening, diagnosis, and treatment. Harbinger Health merges artificial intelligence advancements with its understanding of the biology of early-stage cancer to detect cancer even before it becomes visible or shows symptoms. Their goal is to develop a comprehensive blood test for multiple types of cancer.

The company will use the April 2026 funding to advance its Harbinger HX platform and bring the Resolve blood-based multi-cancer detection tests to market.

## Funding rounds

- Series B, Sep 28, 2023, $140M — Flagship Pioneering, Catalyst, Pictet Group, Partners Investment, M&G

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series B
- Catalyst (https://capitalatlas.ai/funds/catalyst) — Series B
- Pictet Group — Series B
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series B
- M&G (https://capitalatlas.ai/funds/m-g) — Series B